Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Awakn Starts Patient Screening For Alcohol Disorder Trial with AWKN-001
Details : AWKN-001 (ketamine) is an investigational consisting of an N-methyl-D-aspartate receptor-modulating drug, a novel medication-assisted treatment for severe AUD.
Brand Name : AWKN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 12, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?